688505.SS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 10:00):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
Šios dienos apimtis	2.95M
Vidutinė apimtis	3.20M
Rinkos kapitalizacija	652.35M
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	70.27
ATR14	CNY0.0100 (0.13%)

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: -0.49 (neutral)

Signal:(39.4) Neutral

Shanghai Fudan-Zhangjiang Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Shanghai Fudan-Zhangjiang Koreliacija - Valiuta/Žaliavos

0.14
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.24
( neutral )

0.18
( neutral )

0.54
( weak )

Shanghai Fudan-Zhangjiang Finansinės ataskaitos

Annual	2023
Pajamos:	CNY845.34M
Bruto pelnas:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2023
Pajamos:	CNY845.34M
Bruto pelnas:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2022
Pajamos:	CNY1.03B
Bruto pelnas:	CNY947.10M (91.85 %)
EPS:	CNY0.130

FY	2021
Pajamos:	CNY1.14B
Bruto pelnas:	CNY1.06B (92.90 %)
EPS:	CNY0.220

Financial Reports:

No articles found.

Shanghai Fudan-Zhangjiang

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.